Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2021.05.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Wells' Syndrome Associated With Idiopathic Hypereosinophilic Syndrome in a Child: A Case Report.
Cureus
December 2024
Dermatology and Venereology, Faculty of Medicine, Al-Azhar University, Cairo, EGY.
Wells' syndrome is a rare inflammatory disease characterized by recurrent, erythematous plaques with histological flame figures, which can be associated with idiopathic hypereosinophilic syndrome (IHES). We present a case of a nine-year-old boy who presented with a one-year history of an itchy rash on his legs associated with peripheral eosinophilia. The rash initially started as an annular plaque and developed raised borders with central hyperpigmentation.
View Article and Find Full Text PDFPoor agreement among asthma specialists on the choice and timing of initiation of a biologic treatment for severe asthma patients.
J Allergy Clin Immunol Pract
January 2025
Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care Global, Cambridge, UK; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom. Electronic address:
Background: As the number of monoclonal antibodies available for severe asthma is growing, specialists currently choose without clear guidelines. Despite increasing knowledge on treatment response to these monoclonal antibodies, making the optimal choice for each individual patient remains a challenge. However, evidence of this daily challenge is lacking.
View Article and Find Full Text PDFLongitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients treated with dupilumab.
J Allergy Clin Immunol
January 2025
National Jewish Health, Denver, CO, USA. Electronic address:
Background: Inhibition of IL-4/IL-13 driven inflammation by dupilumab has shown significant clinical benefits in treatment of atopic dermatitis (AD).
Objective: To assess longitudinal protein and metabolite composition in AD skin during dupilumab treatment.
Methods: Skin tape strip (STS) were collected from lesional/non-lesional skin of 20 AD patients during 16-week dupilumab treatment and from 20 healthy volunteers (HV) followed for 16-weeks.
Dupilumab treatment restores lesional and non-lesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD).
J Am Acad Dermatol
January 2025
National Jewish Health, Denver, Colorado. Electronic address:
Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic Response.
Clin Transl Gastroenterol
January 2025
Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
Introduction: We assessed potential mechanisms behind the requirement for more frequent dupilumab dosing in eosinophilic esophagitis (EoE) compared with other approved indications.
Methods: Results for the phase 3 LIBERTY EoE TREET study coprimary endpoints (proportion of patients achieving a peak intraepithelial eosinophil count of ≤6 eosinophils per high-power field and absolute change from baseline in Dysphagia Symptom Questionnaire total score) were pooled in exposure-response analyses.
Results: A steep initial relationship then plateau was observed between higher dupilumab steady-state trough concentrations and decreased eosinophilic infiltration at week 24, whereas a graded exposure-response relationship was observed for symptomatic improvement at week 24.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!